273 related articles for article (PubMed ID: 8142663)
1. Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis.
Li CR; Greenberg PD; Gilbert MJ; Goodrich JM; Riddell SR
Blood; 1994 Apr; 83(7):1971-9. PubMed ID: 8142663
[TBL] [Abstract][Full Text] [Related]
2. Prophylactic ganciclovir is more effective in HLA-identical family member marrow transplant recipients than in more heavily immune-suppressed HLA-identical unrelated donor marrow transplant recipients. Australasian Bone Marrow Transplant Study Group.
Atkinson K; Arthur C; Bradstock K; Dale B; Downs K; Gibson J; Golenia M; Ho J; Joshua D; Juttner C
Bone Marrow Transplant; 1995 Sep; 16(3):401-5. PubMed ID: 8535313
[TBL] [Abstract][Full Text] [Related]
3. Management of allogeneic bone marrow transplant recipients at risk for cytomegalovirus disease using a surveillance bronchoscopy and prolonged pre-emptive ganciclovir therapy.
Reddy V; Hao Y; Lipton J; Meharchand J; Minden M; Mazzulli T; Chan C; Messner HA
J Clin Virol; 1999 Aug; 13(3):149-59. PubMed ID: 10443791
[TBL] [Abstract][Full Text] [Related]
4. Immune reconstitution to cytomegalovirus after allogeneic hematopoietic stem cell transplantation: impact of host factors, drug therapy, and subclinical reactivation.
Hakki M; Riddell SR; Storek J; Carter RA; Stevens-Ayers T; Sudour P; White K; Corey L; Boeckh M
Blood; 2003 Oct; 102(8):3060-7. PubMed ID: 12843000
[TBL] [Abstract][Full Text] [Related]
5. Ganciclovir. An update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients.
Noble S; Faulds D
Drugs; 1998 Jul; 56(1):115-46. PubMed ID: 9664203
[TBL] [Abstract][Full Text] [Related]
6. Different kinetics in anti-cytomegalovirus immunity reconstitution evaluated by lymphocyte proliferation and IFN-gamma production in allogeneic and autologous bone marrow transplantation.
Mendes AV; Benard G; Pereira CB; Kallas EG; Duarte AJ; Pannuti CS; Dulley FL; Machado CM
Acta Haematol; 2002; 107(4):187-94. PubMed ID: 12053145
[TBL] [Abstract][Full Text] [Related]
7. Randomized clinical trial of ganciclovir vs acyclovir for prevention of cytomegalovirus antigenemia after allogeneic transplantation.
Burns LJ; Miller W; Kandaswamy C; DeFor TE; MacMillan ML; Van Burik JA; Weisdorf DJ
Bone Marrow Transplant; 2002 Dec; 30(12):945-51. PubMed ID: 12476289
[TBL] [Abstract][Full Text] [Related]
8. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo-controlled, double-blind trial.
Winston DJ; Ho WG; Bartoni K; Du Mond C; Ebeling DF; Buhles WC; Champlin RE
Ann Intern Med; 1993 Feb; 118(3):179-84. PubMed ID: 8380243
[TBL] [Abstract][Full Text] [Related]
9. Cytotoxic T cells specific for cytomegalovirus: a potential therapy for immunocompromised patients.
Riddell SR; Reusser P; Greenberg PD
Rev Infect Dis; 1991; 13 Suppl 11():S966-73. PubMed ID: 1664137
[TBL] [Abstract][Full Text] [Related]
10. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation.
Goodrich JM; Mori M; Gleaves CA; Du Mond C; Cays M; Ebeling DF; Buhles WC; DeArmond B; Meyers JD
N Engl J Med; 1991 Dec; 325(23):1601-7. PubMed ID: 1658652
[TBL] [Abstract][Full Text] [Related]
11. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor.
Walter EA; Greenberg PD; Gilbert MJ; Finch RJ; Watanabe KS; Thomas ED; Riddell SR
N Engl J Med; 1995 Oct; 333(16):1038-44. PubMed ID: 7675046
[TBL] [Abstract][Full Text] [Related]
12. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant.
Goodrich JM; Bowden RA; Fisher L; Keller C; Schoch G; Meyers JD
Ann Intern Med; 1993 Feb; 118(3):173-8. PubMed ID: 8380242
[TBL] [Abstract][Full Text] [Related]
13. Cytomegalovirus-specific T-cell immunity in recipients of autologous peripheral blood stem cell or bone marrow transplants.
Reusser P; Attenhofer R; Hebart H; Helg C; Chapuis B; Einsele H
Blood; 1997 May; 89(10):3873-9. PubMed ID: 9160696
[TBL] [Abstract][Full Text] [Related]
14. Ganciclovir three times per week is not adequate to prevent cytomegalovirus reactivation after T cell-depleted marrow transplantation.
Przepiorka D; Ippoliti C; Panina A; Goodrich J; Giralt S; van Besien K; Mehra R; Deisseroth AB; Andersson B; Luna M
Bone Marrow Transplant; 1994 Apr; 13(4):461-4. PubMed ID: 8019472
[TBL] [Abstract][Full Text] [Related]
15. Comparison of cytomegalovirus antigenemia and shell vial culture in allogeneic marrow transplantation recipients receiving ganciclovir prophylaxis.
Nicholson VA; Whimbey E; Champlin R; Abi-Said D; Przepiorka D; Tarrand J; Chan K; Bodey GP; Goodrich JM
Bone Marrow Transplant; 1997 Jan; 19(1):37-41. PubMed ID: 9012929
[TBL] [Abstract][Full Text] [Related]
16. Effect of long-term prophylaxis in the development of cytomegalovirus-specific T-cell immunity in D+/R- solid organ transplant recipients.
San-Juan R; Navarro D; García-Reyne A; Montejo M; Muñoz P; Carratala J; Len O; Fortun J; Muñoz-Cobo B; Gimenez E; Eworo A; Sabe N; Meije Y; Martín-Davila P; Andres A; Delgado J; Jimenez C; Amat P; Fernández-Ruiz M; López-Medrano F; Lumbreras C; Aguado JM;
Transpl Infect Dis; 2015 Oct; 17(5):637-46. PubMed ID: 26134282
[TBL] [Abstract][Full Text] [Related]
17. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study.
Boeckh M; Gooley TA; Myerson D; Cunningham T; Schoch G; Bowden RA
Blood; 1996 Nov; 88(10):4063-71. PubMed ID: 8916975
[TBL] [Abstract][Full Text] [Related]
18. Ganciclovir prophylaxis for cytomegalovirus infection in pediatric allogeneic bone marrow transplant recipients.
Canpolat C; Culbert S; Gardner M; Whimbey E; Tarrand J; Chan KW
Bone Marrow Transplant; 1996 Apr; 17(4):589-93. PubMed ID: 8722360
[TBL] [Abstract][Full Text] [Related]
19. Reconstitution of HLA-A*2402-restricted cytomegalovirus-specific T-cells following stem cell transplantation.
Gondo H; Himeji D; Kamezaki K; Numata A; Tanimoto T; Takase K; Aoki K; Henzan H; Nagafuji K; Miyamoto T; Ishikawa F; Shimoda K; Inaba S; Tsukamoto H; Horiuchi T; Nakashima H; Otsuka T; Kato K; Kuroiwa M; Higuchi M; Shibuya T; Kamimura T; Kuzushima K; Tsurumi T; Kanda Y; Harada M
Int J Hematol; 2004 Dec; 80(5):441-8. PubMed ID: 15646657
[TBL] [Abstract][Full Text] [Related]
20. A pilot phase II study of alternate day ganciclovir and foscarnet in preventing cytomegalovirus (CMV) infections in at-risk pediatric and adolescent allogeneic stem cell transplant recipients.
Shereck EB; Cooney E; van de Ven C; Della-Lotta P; Cairo MS
Pediatr Blood Cancer; 2007 Sep; 49(3):306-12. PubMed ID: 16972242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
